Syntimmune

About:

Syntimmune develops differentiated drug candidates in a wide range of autoimmune diseases.

Twitter/X: syntimmune

Top Investors: Apple Tree Partners, Partners Innovation Fund, Baxalta Ventures

Description:

Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumberg founded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts.

Total Funding Amount:

$76M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)syntimmune.com

Founders:

Laurence Blumberg, Richard Blumberg

Number of Employees:

1-10

Last Funding Date:

2017-06-21

IPO Status:

Private

Industries: